Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase NA 1Phase 1 1

Status

Recruiting 2Not yet recruiting 1Completed 1Active not recruiting 1

Sponsor Class

OTHER 3NIH 2

Study Type

Interventional 4Observational 1

Sponsor

Cancer Type

CNS 6Thoracic 5Genitourinary 4Sarcoma 3Head & Neck 2Gastrointestinal 2Other solid neoplasm 1Gynecologic 1Endocrine 1Dermatologic 1Breast 1

Conditions

Lung Neoplasms 4Carcinoma, Non-Small-Cell Lung 3Sarcoma 1Melanoma 1Colorectal Neoplasms 1

Interventions

Carboplatin 347pembrolizumab 322Pemetrexed 246Cisplatin 218Paclitaxel 147Nivolumab 138durvalumab 133osimertinib 112Docetaxel 111atezolizumab 109Specimen Handling 91Radiotherapy 87Drug Therapy 85Magnetic Resonance Spectroscopy 77Etoposide 76Radiosurgery 72Gemcitabine 71Ipilimumab 55130-nm albumin-bound paclitaxel 54Bevacizumab 52cemiplimab 47tislelizumab 44Blood Specimen Collection 40Cetuximab 35Taxes 34Platinum 33Injections 33Biopsy 33Standard of Care 31Immunoglobulin G 30

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Contrast Media × Thoracic × 1 year × Clear all
NCT03191149 2026-05-18

Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change

National Cancer Institute (NCI)

Phase 2 Recruiting
46 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT04430725 2026-05-05

Microwave Ablation or Wedge Resection for the Treatment of Lung, Sarcoma and Colorectal Lesions, ALLUME Study

M.D. Anderson Cancer Center

Active not recruiting
74 enrolled
GastrointestinalSarcomaThoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Sarcoma, Colorectal Neoplasms

NCT07492121 2026-03-25

GAPIMET

University of Zurich

Phase 2 Not yet recruiting
180 enrolled
DermatologicThoracic

Lung Neoplasms, Melanoma

NCT04751747 2026-01-30

Adaptive Radiation Planning for the Reduction of Radiation-Induced Toxicity in Patients With Stage II-IV Non-small Cell Lung Cancer

Rutgers, The State University of New Jersey

Phase NA Recruiting
34 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT03801902 2025-09-23

Testing the Safety of Adding Either Monalizumab (IPH2201) or Oleclumab (MEDI9447) to Durvalumab (MEDI4736) Plus Standard Radiation Therapy for Locally Advanced Non-small Cell Lung Cancer (NSCLC), ARCHON-1 Trial

National Cancer Institute (NCI)

Phase 1 Completed
26 enrolled 17 charts
Thoracic

Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡